What is HC Wainwright’s Forecast for Ocugen FY2026 Earnings?

Ocugen, Inc. (NASDAQ:OCGN) – HC Wainwright raised their FY2026 earnings per share estimates for Ocugen in a research note issued on Monday, September 28th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.27) for the year, up from their prior estimate of ($0.28). The consensus estimate for Ocugen’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Ocugen’s Q4 2026 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at ($0.39) EPS and FY2030 earnings at $0.99 EPS.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.49 million during the quarter, compared to analysts’ expectations of $0.89 million.

Other research analysts also recently issued reports about the stock. Weiss Ratings upgraded shares of Ocugen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wall Street Zen lowered shares of Ocugen from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ocugen has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

Ocugen Stock Performance

Shares of OCGN opened at $1.00 on Wednesday. The stock has a market capitalization of $339.11 million, a PE ratio of -3.85 and a beta of 2.27. The business’s fifty day moving average price is $1.23 and its 200 day moving average price is $1.44. The company has a debt-to-equity ratio of 4.17, a current ratio of 0.80 and a quick ratio of 0.80. Ocugen has a 12-month low of $0.97 and a 12-month high of $2.73.

Insider Activity

In other news, CEO Shankar Musunuri sold 468,727 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $1.12, for a total transaction of $524,974.24. Following the completion of the transaction, the chief executive officer owned 4,487,197 shares of the company’s stock, valued at approximately $5,025,660.64. The trade was a 9.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.95% of the company’s stock.

Institutional Trading of Ocugen

Several hedge funds have recently added to or reduced their stakes in the business. Diversify Advisory Services LLC bought a new position in Ocugen during the 2nd quarter valued at $25,000. GTS Securities LLC bought a new stake in shares of Ocugen in the 2nd quarter worth $27,000. Engineers Gate Manager LP raised its stake in shares of Ocugen by 70.2% in the 2nd quarter. Engineers Gate Manager LP now owns 18,368 shares of the company’s stock worth $28,000 after buying an additional 7,577 shares in the last quarter. CTC Alternative Strategies Ltd. acquired a new stake in shares of Ocugen in the first quarter valued at $34,000. Finally, Legal & General Group Plc acquired a new stake in shares of Ocugen in the second quarter valued at $51,000. Institutional investors own 10.27% of the company’s stock.

More Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised multiple earnings forecasts. The analyst improved estimates for Ocugen’s Q4 2026, full-year 2026, quarterly and full-year 2027, and full-year 2028 results, generally reflecting narrower expected losses. The FY2027 loss forecast improved to $0.32 per share from $0.36, while the FY2028 loss estimate improved to $0.39 from $0.43. HC Wainwright also increased its FY2030 earnings forecast to $0.99 per share from $0.98, suggesting longer-term confidence in the company’s potential commercialization and earnings trajectory.
• Positive Sentiment: Ocugen will present its gene-therapy platform at upcoming scientific conferences. The company plans to highlight its modifier gene therapy platform, which is focused on treatments for blindness-related diseases. Conference visibility could help build investor interest and provide opportunities for additional scientific or development updates. Ocugen to Participate in Upcoming Scientific Conferences
• Neutral Sentiment: The estimate revisions are incremental rather than a shift to near-term profitability. HC Wainwright still projects losses through 2028, including a $0.27-per-share loss for 2026 and a $0.32-per-share loss for 2027. The improved forecasts may support sentiment, but investors will likely need clinical progress, regulatory milestones, or stronger revenue growth for a sustained recovery.

About Ocugen

Ocugen, Inc (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and other serious medical conditions. The company’s ophthalmology pipeline includes modifier gene therapies designed to address inherited retinal diseases, including retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration.

Ocugen’s leading candidates include OCU400, an investigational gene therapy for certain inherited retinal diseases, and OCU410 and OCU410ST, investigational therapies being developed for geographic atrophy and Stargardt disease, respectively.